US-based biotechnology firm Novavax has started enrolling participants in a Phase I/II clinical trial of its Covid-19 vaccine candidate, NVX‑CoV2373, in Australia.
Developed using the company’s nanoparticle technology, NVX‑CoV2373 is engineered from the genetic sequence of SARS‑CoV‑2.
The Phase I/II trial comprises two parts. The Phase I part is a randomised, observer-blinded, placebo-controlled study assessing the immunogenicity and safety of the vaccine candidate, adjuvanted with Matrix‑M, as well as unadjuvanted.
It is recruiting around 130 healthy participants aged 18 to 59 years at two sites in Australia.
Share this article
